| Browse All

Tenax Therapeutics, Inc. (TENX)

Healthcare | Biotechnology | Chapel Hill, United States | NasdaqCM
14.45 USD +0.97 (7.196%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 14.88 +0.43 (2.976%) ⇧ (April 17, 2026, 7:34 p.m. EDT)

Short-term: ★★☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 4:18 p.m. EDT

TENX is a high-risk, high-reward biotech stock with a volatile price history and no dividend payouts. The recent price movement shows some momentum above the 200-day average, but fundamentals are weak with negative earnings and low profitability. Analysts are cautiously optimistic, but the stock's low market cap and lack of consistent dividends make it a speculative play. Short-term traders may consider buying calls if the stock continues its upward trend, while long-term investors should be cautious due to the lack of fundamentals and high risk.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.482574
AutoETS0.607168
AutoARIMA0.621462
MSTL0.629063

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 52%
H-stat 3.31
Ljung-Box p 0.000
Jarque-Bera p 0.062
Excess Kurtosis 0.07
Attribute Value
Sector Healthcare
Market Cap 248,505,488
Forward P/E -9.88
Beta 1.19
Website https://www.tenaxthera.com

As of April 11, 2026, 4:18 p.m. EDT: The options data suggests mixed sentiment. For the May 15 expiration, there is moderate call activity around the ATM strike of 15.0 with high IV, indicating potential bullish speculation, but no significant put activity. For the October 16 expiration, there is increased call activity around the 15.0 strike, with higher IV, suggesting some bullish expectations, while put activity is limited, indicating less bearish sentiment. Overall, the options market does not show strong directional bias, but there is some speculative interest in the stock's upward movement.


Info Dump

Attribute Value
52 Week Change 1.8112841
Address1 101 Glen Lennox Drive
Address2 Suite 300
All Time High 21,600,000.0
All Time Low 2.77
Ask 14.5
Ask Size 6
Average Analyst Rating 1.1 - Strong Buy
Average Daily Volume10 Day 577,970
Average Daily Volume3 Month 360,127
Average Volume 360,127
Average Volume10Days 577,970
Beta 1.187
Bid 14.18
Bid Size 6
Book Value 2.288
City Chapel Hill
Compensation As Of Epoch Date 1,735,603,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 14.45
Current Ratio 14.565
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 14.5
Day Low 13.11
Display Name Tenax Therapeutics
Dividend Date 1,519,603,200
Earnings Timestamp End 1,755,288,000
Earnings Timestamp Start 1,754,942,400
Ebitda Margins 0.0
Enterprise Value 629,275,648
Eps Current Year -1.55667
Eps Forward -1.462
Eps Trailing Twelve Months -1.34
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 13.5227
Fifty Day Average Change 0.9272995
Fifty Day Average Change Percent 0.06857354
Fifty Two Week Change Percent 181.1284
Fifty Two Week High 18.38
Fifty Two Week High Change -3.9299994
Fifty Two Week High Change Percent -0.21381934
Fifty Two Week Low 4.63
Fifty Two Week Low Change 9.82
Fifty Two Week Low Change Percent 2.1209502
Fifty Two Week Range 4.63 - 18.38
Financial Currency USD
First Trade Date Milliseconds 765,466,200,000
Float Shares 17,165,511
Forward Eps -1.462
Forward P E -9.88372
Free Cashflow -18,441,624
Full Exchange Name NasdaqCM
Full Time Employees 14
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Held Percent Insiders 0.0011100001
Held Percent Institutions 0.46618998
Implied Shares Outstanding 17,197,613
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,704,240,000
Last Split Factor 1:80
Long Business Summary Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia. The company was formerly known as Oxygen Biotherapeutics, Inc. and changed its name to Tenax Therapeutics, Inc. in September 2014. Tenax Therapeutics, Inc. was founded in 1967 and is headquartered in Chapel Hill, North Carolina.
Long Name Tenax Therapeutics, Inc.
Market us_market
Market Cap 248,505,488
Market State CLOSED
Max Age 86,400
Message Board Id finmb_389766
Most Recent Quarter 1,767,139,200
Net Income To Common -52,599,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 248,505,507
Number Of Analyst Opinions 7
Open 13.7
Operating Cashflow -35,800,000
Operating Margins 0.0
Payout Ratio 0.0
Peg Ratio 1.44
Phone 919 855 2100
Post Market Change 0.4300003
Post Market Change Percent 2.9757807
Post Market Price 14.88
Post Market Time 1,776,468,871
Previous Close 13.48
Price Eps Current Year -9.282636
Price Hint 2
Price To Book 6.315559
Profit Margins 0.0
Quick Ratio 13.634
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.14286
Region US
Regular Market Change 0.97
Regular Market Change Percent 7.19585
Regular Market Day High 14.5
Regular Market Day Low 13.11
Regular Market Day Range 13.11 - 14.5
Regular Market Open 13.7
Regular Market Previous Close 13.48
Regular Market Price 14.45
Regular Market Time 1,776,456,000
Regular Market Volume 763,408
Return On Assets -0.3508
Return On Equity -0.55641
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 17,197,613
Shares Percent Shares Out 0.01
Shares Short 172,743
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 120,380
Short Name Tenax Therapeutics, Inc.
Short Percent Of Float 0.0101
Short Ratio 0.42
Source Interval 15
State NC
Symbol TENX
Target High Price 35.0
Target Low Price 20.0
Target Mean Price 29.57143
Target Median Price 30.0
Total Cash 97,565,000
Total Cash Per Share 1.94
Total Debt 0
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.34
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 9.715525
Two Hundred Day Average Change 4.734475
Two Hundred Day Average Change Percent 0.4873103
Type Disp Equity
Volume 763,408
Website https://www.tenaxthera.com
Zip 27,517